Evoke Pharma (NASDAQ: EVOK) Q2 2025 results press release filed with SEC

Rhea-AI Filing Summary

Evoke Pharma, Inc. filed a current report to note that it issued a press release on August 14, 2025 announcing its financial results for the three- and six-month periods ended June 30, 2025. The press release is provided as Exhibit 99.1 to the report and is incorporated by reference, while the company clarifies that this earnings information is being furnished rather than filed for liability purposes under the securities laws.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

0001403708false00014037082025-08-142025-08-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2025

EVOKE PHARMA, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-36075	20-8447886
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
420 Stevens Avenue, Suite 230
Solana Beach, California				92075
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 858 345-1494

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		EVOK		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2025, Evoke Pharma, Inc. issued a press release announcing its financial results for the three and six-month periods ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release issued on August 14, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			EVOKE PHARMA, INC.
Date:	August 14, 2025	By:	/s/ Matthew J. D'Onofrio
			Name: Matthew J. D'Onofrio Title: Chief Executive Officer and Director

FAQ

What did Evoke Pharma (EVOK) disclose in this 8-K filing?

Evoke Pharma disclosed that it issued a press release on August 14, 2025 announcing its financial results for the three- and six-month periods ended June 30, 2025, and attached that press release as Exhibit 99.1.

Which financial periods are covered by Evoke Pharmas latest results release?

The press release furnished with the report covers Evoke Pharmas financial results for the three- and six-month periods ended June 30, 2025.

How is the earnings press release treated under the securities laws in this EVOK 8-K?

The company states that the information in the report, including Exhibit 99.1, is furnished under Item 2.02 and is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934.

What exhibits are included with Evoke Pharmas Q2 2025 results 8-K?

The report includes Exhibit 99.1, which is the press release issued on August 14, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Who signed Evoke Pharmas 8-K related to the June 30, 2025 results?

The report was signed on behalf of Evoke Pharma, Inc. by Matthew J. DOnofrio, who is identified as Chief Executive Officer and Director.